Live video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer will participate in a virtual investor webinar hosted by Ladenburg Thalmann on Thursday, August 21, 2025 and 1:00 PM ET. The webinar will be moderated by Jeffre ...

Unlike traditional monofocal or multifocal intraocular lenses, the Ocumetics Lens is designed to work with the natural movements of the eye, potentially restoring the ability to see both distant and near objects clearly without glasses or contacts following cataract surgery. The Company will now continue its first-in-human clinical trial program, with additional implantations scheduled over the coming months. Each step brings Ocumetics closer to validating the safety and performance of the Ocumetics Lens, p ...

Core Viewpoint - Zynex, Inc. has appointed Steven Dyson as the new CEO and announced a new executive leadership team to enhance business performance and fulfill its mission in the medical technology sector [1][2][7]. Leadership Appointments - Steven Dyson has been appointed as CEO, effective June 30, 2025, and has since been working with the Board to finalize the executive team [2]. - Vikram Bajaj joins as Chief Financial Officer, bringing over 20 years of experience in finance and M&A within the med-tech sector, previously serving as CFO at Vyaire Medical and Kepro [3]. - John Bibb has been appointed as Chief Legal Officer, with over 20 years of experience in legal and compliance roles in the med-tech sector, including positions at Kinetic Concepts and Vyaire Medical [4]. - Ajay Gopal is the new EVP of Sales, recognized for his leadership in the healthcare and medical device sectors, with a history of transformative growth [5]. - Agnes Powell has been appointed as VP of Billing, with 20 years of experience in revenue cycle operations and compliance across various healthcare settings [6]. Executive Team Goals - The new executive team aims to improve business performance and uphold integrity in business practices, focusing on enhancing the quality of life for patients suffering from pain and illness [7]. - The Board expresses confidence in the new leadership team to drive Zynex towards greater success [7].

Core Insights - The AVALON study published in the American Journal of Managed Care reinforces the clinical superiority of iRhythm Technologies' Zio long-term continuous monitoring (LTCM) service among commercially insured patients, demonstrating its effectiveness compared to other ambulatory cardiac monitoring (ACM) modalities [1][2][3] Study Findings - AVALON is the largest real-world study of its kind, involving 428,707 commercially insured patients, and shows that the Zio LTCM service has the highest diagnostic yield, fastest time to diagnosis, and lowest total healthcare costs compared to other monitoring modalities [4][6][11] - The Zio LTCM service was associated with a 2.04 times higher likelihood of new arrhythmia diagnosis within 90 days compared to Holter monitors, and 1.69 times compared to ambulatory event monitors (AEM) [8][12] - The median time from end-of-wear to arrhythmia diagnosis for the Zio LTCM service was 9 days, significantly faster than Holter (12 days) and AEM (30 days) [12] - The Zio LTCM service demonstrated the lowest total medical and pharmacy costs at $10,476 per patient-year, compared to Holter ($11,042), AEM ($11,492), and non-iRhythm LTCM services ($11,293) [12] Clinical Implications - The findings indicate that the Zio LTCM service leads to lower healthcare resource utilization, including fewer emergency department visits and hospitalizations, and a lower likelihood of cardiovascular events [11][12] - The study confirms that the Zio LTCM service's advantages extend across diverse patient populations and payer segments, building on previous findings from the Medicare-focused CAMELOT study [6][13] Company Commitment - iRhythm Technologies emphasizes its commitment to delivering clinically meaningful innovations that drive value across the healthcare system, as highlighted by the results of the AVALON study [3][10][14]

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BDX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am not ...

FORT MILLS, S.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced registration and approval in the United Kingdom for its LockeT product, a suture retention device. LockeT received CE Mark for European approval and distribution in May 2025. Obtaining registration was the final approval required to launch sales in the UK. Catheter Prec ...

Group 1: Intuitive Surgical - Intuitive Surgical is a leader in robotic-assisted surgery (RAS) devices, primarily driven by its da Vinci system, which allows for minimally invasive surgeries across various medical fields [4] - The company has faced challenges such as a decline in bariatric surgeries and tariffs, but its long-term prospects remain strong due to a resilient business model and consistent growth in revenue [5][9] - The addressable market for Intuitive Surgical is underpenetrated, with over half of its revenue coming from instruments and accessories tied to procedure volume, benefiting from an aging global population [7][8] - Intuitive Surgical has outperformed the market for 25 years, indicating potential for significant capital growth for younger investors [9] Group 2: Moderna - Moderna is considered a riskier investment compared to Intuitive Surgical but has substantial upside potential, particularly due to its successful COVID-19 vaccine and innovative mRNA platform [10] - The company has achieved several clinical and regulatory successes, including approvals for vaccines against RSV and ongoing trials for vaccines targeting influenza and cancer [11][13] - Despite a recent lag in stock performance due to declining sales from its coronavirus vaccine franchise, Moderna's pipeline remains promising, with potential candidates for various cancers and an early-stage HIV vaccine [12][14] - If Moderna successfully mainstreams mRNA vaccines over the next five years, it could lead to significant stock upside, making it a consideration for younger investors who can tolerate volatility [14]

Core Insights - AngioDynamics (ANGO) is undergoing a multi-year transformation and is nearing an inflection point in its business strategy [1] - The company has divested its legacy assets and resolved litigation issues, allowing it to focus on sales growth [1] Company Developments - AngioDynamics has successfully divested from legacy assets, which is a significant step in its transformation process [1] - The resolution of litigation has cleared obstacles for the company, enabling a more concentrated effort on expanding its sales [1] Growth Potential - With the divestiture and litigation resolved, AngioDynamics is positioned to capitalize on growth opportunities in the market [1]

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price, dropping approximately 38% from $26.12 to $16.21 on April 3, 2025, after cutting its 2025 revenue forecast due to a market softening noted in the second half of 2024 [5]. - Following another revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 on July 9, 2025 [6].

Core Viewpoint - The article highlights three dividend stocks—Coca-Cola, Realty Income, and Johnson & Johnson—that provide steady income and have a proven track record of performance across various economic conditions [1][2]. Group 1: Coca-Cola - Coca-Cola is a globally recognized brand with a diverse product portfolio beyond colas, including Dasani water and Minute Maid juice [4]. - The company has raised its dividend for 63 consecutive years, making it a Dividend King, with a current yield just below 3% and a payout ratio that allows for steady increases [5]. - Despite potential headwinds from currency fluctuations and health trends affecting sugary beverage sales, Coca-Cola's adaptability keeps it in a reliable position [6]. Group 2: Realty Income - Realty Income, known as "The Monthly Dividend Company," has paid dividends for 661 consecutive months, approximately 55 years [7]. - The company operates on a business model of long-term net lease agreements with tenants in stable industries, owning over 15,600 commercial properties with a 98.5% occupancy rate [8]. - Realty Income's predictable cash flow supports a current yield of around 5.6%, and while elevated interest rates have impacted share prices, the fundamentals remain strong [9][10]. Group 3: Johnson & Johnson - Johnson & Johnson is another Dividend King, having increased its annual dividend for 63 years, with operations in pharmaceuticals and medical devices [11][12]. - The pharmaceutical segment generates the largest revenue share, while the medical devices segment benefits from consistent demand [12]. - Despite facing litigation risks, the company maintains a strong balance sheet and a payout ratio just over 50%, supporting a dividend yield of about 3% [13][14]. Group 4: Overall Investment Perspective - The three companies—Coca-Cola, Realty Income, and Johnson & Johnson—demonstrate a long history of rewarding shareholders through various market cycles, providing a stable income stream even amidst market volatility [15].